Our Pipeline

We are programming biology to create optimal therapeutics for the greatest impact on human health.

Program Target Indication Phase Collaborations
Generating IND Enabling Phase 1 Phase 2 Phase 3
Immunology
GB-0895 TSLP Severe Asthma

Phase Phase 1 Completed

GB-0895 TSLP
GB-0895 TSLP COPD

Phase Phase 1

GB-7624 IL-13 Atopic Dermatitis

Phase Phase 1

Bispecific TSLP x IL-13 Atopic Dermatitis

Phase Generating

GB-6537 TL1A Ulcerative Colitis

Phase IND Enabling

GB-4558 OX40L Atopic Dermatitis

Phase IND Enabling

Bispecific TL1A x IL-23 Ulcerative Colitis

Phase Generating

Oncology
GB-5267 Undisclosed Advanced Solid Tumors

Phase IND Enabling

Collaborations

Roswell Park Logo 50/50
Bispecific Undisclosed NSCLC

Phase Generating

Collaborations

The University of Texas
MD Anderson Cancer Center
50/50
GB-4362 Free MMAE ADC Toxin Neutralizer

Phase IND Enabling

Infectious Disease
GB-0669* SARS-CoV-2 S2 Covid-19

Phase Phase 1 Completed

Undisclosed
Amgen
6 Undisclosed Programs

Collaborations

Novartis
Multiple Undisclosed Programs

Collaborations

*Deprioritized for internal development

Policy on Expanded Access (EA) to Investigational Drugs

Currently, participation in clinical trials is the only way for patients to gain access to Generate:Biomedicines’ investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.